In recent years, clinical studies have shown that immunotherapy (PD-1/L1 monoclonal antibody, CTLA-4 inhibitor) has great potential in the treatment of lung cancer patients without epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations [4]. This evidence concerns the gene EGFR and lung cancer.